Geode Capital Management LLC Purchases 102,869 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Geode Capital Management LLC raised its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 22.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 563,009 shares of the company's stock after acquiring an additional 102,869 shares during the quarter. Geode Capital Management LLC owned approximately 0.90% of Corvus Pharmaceuticals worth $2,974,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Cubist Systematic Strategies LLC purchased a new position in Corvus Pharmaceuticals in the second quarter valued at about $44,000. Nwam LLC acquired a new position in Corvus Pharmaceuticals in the third quarter worth approximately $53,000. XTX Topco Ltd acquired a new position in Corvus Pharmaceuticals in the third quarter worth approximately $74,000. Oppenheimer & Co. Inc. bought a new position in Corvus Pharmaceuticals during the third quarter valued at approximately $89,000. Finally, Marshall Wace LLP acquired a new stake in Corvus Pharmaceuticals in the second quarter valued at approximately $136,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CRVS. Mizuho raised shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH upped their price target on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a "buy" rating in a research note on Monday, September 16th. HC Wainwright started coverage on Corvus Pharmaceuticals in a research note on Thursday, January 2nd. They issued a "buy" rating and a $11.00 price objective on the stock. Oppenheimer upped their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. Finally, StockNews.com lowered shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $12.38.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS traded down $0.10 during mid-day trading on Wednesday, hitting $5.65. The company's stock had a trading volume of 388,883 shares, compared to its average volume of 697,137. The stock's 50-day moving average is $7.56 and its two-hundred day moving average is $5.39. The firm has a market capitalization of $363.05 million, a PE ratio of -6.08 and a beta of 1.07. Corvus Pharmaceuticals, Inc. has a one year low of $1.30 and a one year high of $10.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.